NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma

NCT01351571

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Renal Cell Cancer

Countries: India

This observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with interferon alpha-2a as first-line treatment in patients with advanced and/or metastatic renal cell carcinoma. Data will be collected from each patient as per routine clinical practice of the Investigator (maximum of 52 weeks, until disease progression /unacceptable toxicity or withdrawal of consent) and/or based on the local label.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Advanced and/or metastatic renal cell carcinoma
* Receiving first-line treatment with Avastin and interferon alpha-2a according to standard of care and current local label
* At least one measurable and non-measurable lesion according to RECIST criteria
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Adequate bone marrow, renal and liver function

Exclusion Criteria:

* Contraindications to Avastin and/or interferon alpha-2a as per local label

Locations (2)

Aurangabad, India
Delhi, India